Te pharmacology of muscimol is reasonably well understood. Muscimol is a GABA-A receptor agonist, producing sedative and dissociative effects at sufficient doses (Johnston, 2014). It does not act on serotonin receptors, which distinguishes it pharmacologically from psilocybin and LSD. At the doses appearing in consumer products, typically 3 mg to 10 mg per serving, effects include mild relaxation, altered sensory perception, and sedation. Ibotenic acid is an NMDA receptor agonist and neurotoxic at high doses in animal models, though human clinical data on dose thresholds is limited (Michelot and Melendez-Howell, 2003). Consumer understanding of this pharmacology is, by most
measures, poor. Marketing language in the category tends toward the experiential and the vague. “Legal psychedelic,” “entheogenic,” and “mind-expanding” appear frequently. Te specific receptor mechanisms and the conversion quality question—the factor that most determines whether a product behaves as advertised—are rarely mentioned.
What mycologists can offer Te mycology community has two things this conversation
needs: accurate taxonomy and pharmacology, and credibility with general audiences increasingly drawn to fungi as medicine, food, and experience. Amanita muscaria has a long scientific literature. Te
ethnobotanical record is extensive. Te toxicological data, while not as thorough as clinical drug trials, is more rigorous than most of what appears on consumer product pages. Tere is a real opening for mycologists and mycology-adjacent writers to engage with this market, not as endorsers or critics but as the people who actually know the relevant facts. Whether consumer interest in A. muscaria translates
into durable market demand or regulatory intervention is a question for the next few years. What is not in question is that the mycology community will be better positioned to shape that conversation if it starts now, while the category is still forming, rather than after the narrative has settled without input from people who study the mushroom.
Literature Cited
Aranko, K., E. Vuori, T. Lemmila, and J. Hokkanen. 1985. Pharmacological characteristics of muscimol and ibotenic acid: their decarboxylation products. Archives of Toxicology, Supplement 8: 159–162.
Johnston, G.A.R. 2014. Muscimol as an ionotropic GABA receptor agonist. Neurochemical Research 39(10): 1942–1947.
Louisiana Revised Statutes. 2005. Section 40:989.1, listing Amanita muscaria among Schedule I hallucinogenic substances.
Michelot, D., and L.M. Melendez-Howell. 2003. Amanita muscaria: chemistry, biology, toxicology, and ethnomycology. Mycological Research 107(2): 131–146.
Wasson, R.G. 1968. Soma: Divine Mushroom of Immortality. Harcourt Brace Jovanovich, New York; 381 pp.
Author note: Belle Gibson writes educational content on
botanical compounds. She creates content for Wunder, a botanical supplement company. Te views in this article are her own; no Wunder products or URLs appear in the text. Contact:
promotions@ourwunderland.com.
24 FUNGI Volume 19:2 Summer 2026
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
